Clinical Trial

First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2

Study acronym: EphA2
Recruiting
View on ClinicalTrials.gov →
Summary
Purpose Ephrin type-A receptor 2 (EphA2) is a receptor tyrosine kinase overexpressed in various solid tumors and associated with tumor progression, metastasis, and poor prognosis. However, noninvasive imaging tools for assessing EphA2 expression in vivo remain limited. This study aims to develop a novel 68Ga-labeled EphA2-targeting positron emission tomography (PET) tracer for specific imaging of EphA2-positive malignancies.
Trial Details
NCT Number NCT07593209
Lead Sponsor First Hospital of China Medical University
Conditions Malignant Tumor
Enrollment 30 participants
Start Date 2026-05-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-18